Population pharmacokinetics and effects of indinavir in HIV infected patients.

被引：0
|
作者：
Csajka, C
Marzolini, C
Fattinger, K
Decosterd, LA
Telenti, A
Biollaz, J
Buclin, T
机构：
[1] Univ Lausanne Hosp, Lausanne, Switzerland
[2] Univ Zurich Hosp, CH-8091 Zurich, Switzerland
[3] Univ Lausanne, Lausanne, Switzerland
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2003年 / 73卷 / 02期
关键词：
D O I：
10.1016/S0009-9236(03)90613-8
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：P69 / P69
页数：1
相关论文
共 50 条
  • [41] Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients
    Crommentuyn, KML
    Kappelhoff, BS
    Mulder, JW
    Mairuhu, ATA
    van Gorp, ECM
    Meenhorst, PL
    Huitema, ADR
    Beijnen, JH
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 60 (04) : 378 - 389
  • [42] Population pharmacokinetics of lopinavir/ritonavir (LPVr) in HIV-1-infected patients
    Crommentuyn, KML
    Kappelhoff, BS
    Mulder, JW
    Mairuhu, ATA
    van Gorp, ECM
    Meenhorst, PL
    Huitema, ADR
    Beijnen, JH
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (05) : 609 - 610
  • [43] Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load
    Arnaiz, JA
    Mallolas, J
    Podzamczer, D
    Gerstoft, J
    Lundgren, JD
    Cahn, P
    Fätkenheuer, G
    D'Arminio-Monforte, A
    Casiró, A
    Reiss, P
    Burger, DM
    Stek, M
    Gatell, JM
    AIDS, 2003, 17 (06) : 831 - 840
  • [44] Maintenance of indinavir by dose adjustment in HIV-1-infected patients with indinavir-related toxicity
    Wasmuth, J.-C.
    Lambertz, I.
    Voigt, E.
    Vogel, M.
    Hoffmann, C.
    Burger, D.
    Rockstroh, J. K.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 63 (10) : 901 - 908
  • [45] Maintenance of indinavir by dose adjustment in HIV-1-infected patients with indinavir-related toxicity
    J.-C. Wasmuth
    I. Lambertz
    E. Voigt
    M. Vogel
    C. Hoffmann
    D. Burger
    J. K. Rockstroh
    European Journal of Clinical Pharmacology, 2007, 63 : 901 - 908
  • [46] Indinavir-associated facial lipodystrophy in HIV-infected patients
    Ho, TTY
    Chan, KCW
    Wong, KH
    Lee, SS
    AIDS PATIENT CARE AND STDS, 1999, 13 (01) : 11 - 16
  • [47] Pharmacokinetics (PK) of fusion inhibitor T-20 in HIV-1 infected patients.
    Zhang, X
    Keith, N
    Rodwell, A
    Lang, J
    Rouzier, R
    Dorr, A
    Kolis, S
    Stiles, M
    Kinchelo, T
    Patel, I
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (02) : P27 - P27
  • [48] Population Pharmacokinetics of Dapsone in HIV-Infected Children
    Mark Mirochnick
    Ellen Cooper
    Jing Xu
    Jane Lindsey
    Edmund Capparelli
    Ken McIntosh
    James McNamara
    Lynne M Mofenson
    David Jacobus
    Pediatric Research, 1999, 45 (7) : 168 - 168
  • [49] Population pharmacokinetics of dapsone in HIV-infected children
    Mirochnick, M
    Cooper, E
    Xu, J
    Lindsey, J
    Capparelli, E
    McIntosh, K
    McNamara, J
    Mofenson, LM
    Jacobus, D
    PEDIATRIC RESEARCH, 1999, 45 (04) : 168A - 168A
  • [50] High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy
    Goujard, U
    Legrand, M
    Panhard, X
    Diquet, B
    Duval, X
    Peytavin, G
    Vincent, I
    Katlama, C
    Leport, C
    Bonnet, B
    Salmon-Céron, D
    Mentré, F
    Taburet, AM
    CLINICAL PHARMACOKINETICS, 2005, 44 (12) : 1267 - 1278
12345